Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: Double-blind, randomised, comparative 12-week trial

British Journal of Psychiatry

Volumn 187, Issue SEPT., 2005, Pages 235-242

  Vieta, Eduard ^a   Bourin, Michel ^b   Sanchez, Raymond ^c   Marcus, Ronald ^c   Stock, Elyse ^c   McQuade, Robert ^c   Carson, William ^d   Abou Gharbia, Neveen ^c   Swanink, Rene ^c   Iwamoto, Taro ^e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITÉ DE NANTES   (France)

^c BRISTOL MYERS SQUIBB   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^e OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; PROLACTIN;

ADULT; AKATHISIA; ARTICLE; BIPOLAR I DISORDER; BIPOLAR MANIA; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INSOMNIA; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; STATISTICAL ANALYSIS; TREMOR; YOUNG MANIA RATING SCALE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BODY WEIGHT; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PIPERAZINES; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; TREATMENT OUTCOME;

EID: 24944547903     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.187.3.235     Document Type: Article

References (28)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596-601.
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). Washington, DC: APA.
3. Barnes, T. R. E. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672-676.
4. Bazett, H. C. (1920) An analysis of the time relations of electrocardiograms. Heart, 7, 353-370.
5. Colom, F. & Vieta, E. (2002) Non-adherence in psychiatric disorders: misbehaviour or clinical feature? Acta Psychiatrica Scandinavica, 105, 161-163.
6. Food and Drug Administration (2000) Recommendations for QT Interval Correction (FDA Guidance in Response to Pre-NDA Meeting). Rockville Pike, MD: FDA Division of Neuropharmacological Drug Products.
7. Garfinkel, P. E., Stancer, H. C. & Persuad, E. (1980) A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. Journal of Affective Disorders, 2, 279-288.
8. Kasper, S., Lerman, M., McQuade, R., et al (2003) Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. International Journal of Neuropsychopharmacology, 6, 325-337.
9. Keck, P. E., McElroy, S. L., Strakowski, S. M., et al (1998) 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. American Journal of Psychiatry, 155, 646-652.
10. Keck, P., Marcus, R., Tourkodimitris, S., et al (2003) A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. American Journal of Psychiatry, 160, 1651-1658.
11. Lieberman, J. A. (2004) Dopamine partial agonists: a new class of antipsychotic. CNS Drugs, 18, 251-267.
12. Marder, S. R., McQuade, R. D., Stock, E., et al (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trials. Schizophrenia Research, 61, 123-136.
13. McIntyre, R. M., Brecher, M. & Paulsson, B. (2005) Quetiapine or haloperidol as monotherapy for bipolar mania: a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. European Neuropsychopharmacology, in press.
14. Montgomery, S. A. & Åsberg, M. (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382-389.
15. National Institute of Mental Health (1975) Abnormal Involuntary Movement Scale (AIMS). Early Clinical Drug Evaluation Unit Intercom, 4, 3-6.
16. National Institutes of Health (1998) Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. NIH Publication No. 98-4084. Bethesda, MD: National Institutes of Health.
17. Pigott, T., Carson, W., Saha, A., et al (2003) Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. Journal of Clinical Psychiatry, 64, 1048-1056.
18. Sachs, G. S. & Rush, A. J. (2003) Response, remission, and recovery in bipolar disorders: what are the realistic treatment goals? Journal of Clinical Psychiatry, 64, 18-22.
19. Segal, J., Berk, M., Brook, S. (1998) Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clinical Neuropharmacology, 21, 176-180.
20. Simpson, E. N. & Angus, J. W. F. (1970) A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica Supplementum, 212, 11-19.
21. Smulevich, A. B., Khanna, S., Eerdekens, M., et al (2005) Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by 9-week double-blind trial of risperidone and haloperidol. European Neuropsychopharmacology, 15, 75-84.
22. Spearing, M. K., Post, R. M., Leverich, G. S., et al (1997) Modification of the Clinical Global Impression (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Research, 73, 159-171.
23. Svarstad, B. L., Shireman, T. I. & Sweeney, J. K. (2001) Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatric Services, 52, 805-811.
24. Tohen, M., Baker, R. W., Altshuler, L. L., et al (2002) Olanzapine versus divalproex in the treatment of acute mania. American Journal of Psychiatry, 159, 1001-1007.
25. Tohen, M., Goldberg, J., Gonzalez-Pinto Arillaga, A., et al (2003) A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Archives of General Psychiatry, 60, 1218-1226.
26. Tsai, S. M., Chen, C., Kuo, C., et al (2001) 15-year outcome of treated bipolar disorder. Journal of Affective Disorders, 63, 215-220.
27. Vieta, E. (2003) Atypical antipsychotics in the treatment of mood disorders. Current Opinion in Psychiatry, 16, 23-27.
28. Young, R. C., Biggs, J. T., Ziegler, V. E., et al (1978) A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry, 133, 429-435.